Ocean Biomedical is a 21st century biopharma company that partners with leading scientists and research institutions to accelerate the translation of new discoveries into breakthrough medicines.
We're working to bring together the interdisciplinary expertise and resources required to develop a diverse portfolio of pharmaceutical inventions and technologies through preclinical, clinical, and commercial development. We aim to build a continuous pipeline of drug development opportunities through our relationships with universities and medical centers.
Our current product candidates are licensed from Brown University, Stanford University, and Rhode Island Hospital. Our pipeline consists of both preclinical and clinical-stage programs. We anticipate moving certain preclinical product candidates in our oncology, fibrosis and/or infectious disease platforms, into the clinic in the next 12 to 18 months. We also expect that our anti-inflammatory product candidates licensed from Stanford, will commence Phase 1 clinical trials for the treatment of symptoms of COVID-19, in the first quarter of 2021.
Our programs in oncology and fibrosis are based on discoveries of disease pathways and of related drug targets emerging from pioneering work in the field of chitinase biology by our scientific co-founder, Jack A. Elias, M.D., Dean of Medicine at Brown.
In infectious disease we are developing therapeutic and vaccine candidates against malaria, a disease that kills 500,000 children under the age of five globally each year, that infects 200-300 million people annually worldwide, and for which 3.4 billion people worldwide are at risk. Our product candidates in malaria are based on the discovery by Jonathan Kurtis, M.D., Ph.D., Chair of Pathology and Laboratory Medicine and Director of the M.D./Ph.D. Program at Brown, of two novel malaria antigens, PfSEA-1 and PfGARP which have shown a significant reduction in malaria parasites under testing (press links below).
We're working to bring together the interdisciplinary expertise and resources required to develop a diverse portfolio of pharmaceutical inventions and technologies through preclinical, clinical, and commercial development. We aim to build a continuous pipeline of drug development opportunities through our relationships with universities and medical centers.
Our current product candidates are licensed from Brown University, Stanford University, and Rhode Island Hospital. Our pipeline consists of both preclinical and clinical-stage programs. We anticipate moving certain preclinical product candidates in our oncology, fibrosis and/or infectious disease platforms, into the clinic in the next 12 to 18 months. We also expect that our anti-inflammatory product candidates licensed from Stanford, will commence Phase 1 clinical trials for the treatment of symptoms of COVID-19, in the first quarter of 2021.
Our programs in oncology and fibrosis are based on discoveries of disease pathways and of related drug targets emerging from pioneering work in the field of chitinase biology by our scientific co-founder, Jack A. Elias, M.D., Dean of Medicine at Brown.
In infectious disease we are developing therapeutic and vaccine candidates against malaria, a disease that kills 500,000 children under the age of five globally each year, that infects 200-300 million people annually worldwide, and for which 3.4 billion people worldwide are at risk. Our product candidates in malaria are based on the discovery by Jonathan Kurtis, M.D., Ph.D., Chair of Pathology and Laboratory Medicine and Director of the M.D./Ph.D. Program at Brown, of two novel malaria antigens, PfSEA-1 and PfGARP which have shown a significant reduction in malaria parasites under testing (press links below).
Location: United States, Rhode Island, Providence
Employees: 11-50
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Ambria Cap... | ambriacap.... |
Mentions in press and media 3
| Date | Title | Description |
| 21.06.2023 | Ocean Biomedical (NASDAQ: OCEA) Announces Share Price Target Increase to $17.63 by Fundamental Research Corp. on Positive Results from Independent Study Showing Glioblastoma Tumor Suppression, Receive... | - |
| 01.06.2023 | Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Coverage by Taglich Brothers with a Share Price Target of $20. | /EIN News/ -- Providence, RI, June 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a new-era biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research... |
| 01.06.2023 | Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Coverage by Taglich Brothers with a Share Price Target of $20. | - |